Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

v3.19.3
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Current assets    
Cash and cash equivalents $ 39,409 $ 68,379
Marketable securities - available-for-sale debt securities 63,451 136,755
Accounts receivable, net of allowance for doubtful accounts of $0 and $0   192
Other current assets and prepaid expenses (including current portion of clinical materials) 44,110 25,769
Total current assets 146,970 231,095
Restricted cash 4,318 4,097
Clinical materials 2,485 3,953
Operating lease right-of-use assets, net of accumulated amortization 20,563  
Property, plant and equipment, net of accumulated depreciation of $20818 (2018: $15,924) 31,641 36,118
Intangibles, net of accumulated amortization 2,274 1,473
Total assets 208,251 276,736
Current liabilities    
Accounts payable 5,535 4,083
Operating lease liabilities, current 2,337  
Accrued expenses and other accrued liabilities 26,846 20,354
Deferred revenue 2,683  
Total current liabilities 37,401 24,437
Operating lease liabilities, non-current 22,599  
Other liabilities, non-current 568 5,414
Total liabilities 60,568 29,851
Stockholders' equity    
Common stock - Ordinary shares par value ?0.001, 785,857,300 authorized and 630,952,736 issued and outstanding (2018: 701,103,126 authorized and 627,454,270 issued and outstanding) 943 939
Additional paid in capital 583,065 574,208
Accumulated other comprehensive loss (10,025) (9,763)
Accumulated deficit (426,300) (318,499)
Total stockholders' equity 147,683 246,885
Total liabilities and stockholders' equity $ 208,251 $ 276,736